Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity.

Wang CC, Liao CH, Kuo HC.

Neurourol Urodyn. 2013 Sep 23. doi: 10.1002/nau.22494. [Epub ahead of print]

PMID:
24115083
[PubMed - as supplied by publisher]
2.

Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.

Liao CH, Kuo HC.

J Urol. 2013 May;189(5):1804-10. doi: 10.1016/j.juro.2012.11.089. Epub 2012 Nov 20.

PMID:
23178902
[PubMed - indexed for MEDLINE]
3.

Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.

Kuo HC.

Neurourol Urodyn. 2011 Sep;30(7):1242-8. doi: 10.1002/nau.21054. Epub 2011 May 10.

PMID:
21560152
[PubMed - indexed for MEDLINE]
5.
6.

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder.

Jiang YH, Liao CH, Tang DL, Kuo HC.

PLoS One. 2014 Aug 22;9(8):e105989. doi: 10.1371/journal.pone.0105989. eCollection 2014.

PMID:
25148378
[PubMed - in process]
Free PMC Article
7.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
[PubMed - indexed for MEDLINE]
8.

New therapeutic options for refractory neurogenic detrusor overactivity.

Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L, Fornetti P, Del Zingaro M, Navarra P, Porena M.

Minerva Urol Nefrol. 2004 Mar;56(1):79-87.

PMID:
15195033
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
[PubMed - indexed for MEDLINE]
11.

Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity.

Kuo HC.

J Urol. 2007 Oct;178(4 Pt 1):1359-63. Epub 2007 Aug 16.

PMID:
17706718
[PubMed - indexed for MEDLINE]
12.
13.

Aging and recurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes.

Lin TL, Chen GD, Chen YC, Huang CN, Ng SC.

Taiwan J Obstet Gynecol. 2012 Sep;51(3):381-6. doi: 10.1016/j.tjog.2012.07.011.

PMID:
23040921
[PubMed - indexed for MEDLINE]
14.

Detrusor overactivity in diabetic and non-diabetic patients: is there a difference?

Golabek T, Kiely E, O'Reilly B.

Int Braz J Urol. 2012 Sep-Oct;38(5):652-9; discussion 660.

PMID:
23131522
[PubMed - indexed for MEDLINE]
Free Article
15.

Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.

Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, Thompson C, Li D, Haag-Molkenteller C.

Urology. 2013 Mar;81(3):491-7. doi: 10.1016/j.urology.2012.11.010. Epub 2013 Jan 3.

PMID:
23290144
[PubMed - indexed for MEDLINE]
Free Article
16.

Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.

Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A.

J Urol. 2009 Oct;182(4):1453-7. doi: 10.1016/j.juro.2009.06.023. Epub 2009 Aug 15.

PMID:
19683298
[PubMed - indexed for MEDLINE]
17.

Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.

Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, Marque P, Rischmann P.

Eur Urol. 2008 Mar;53(3):613-8. Epub 2007 Aug 28.

PMID:
17804150
[PubMed - indexed for MEDLINE]
18.

Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.

Giannantoni A, Mearini E, Del Zingaro M, Porena M.

Eur Urol. 2009 Mar;55(3):705-11. doi: 10.1016/j.eururo.2008.08.048. Epub 2008 Sep 2.

PMID:
18814955
[PubMed - indexed for MEDLINE]
19.

Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.

Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M.

J Urol. 2004 Jul;172(1):240-3.

PMID:
15201783
[PubMed - indexed for MEDLINE]
20.

Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.

Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS.

Neurourol Urodyn. 2014 Jun 29. doi: 10.1002/nau.22642. [Epub ahead of print]

PMID:
24975819
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk